Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer (Q79803232)
Jump to navigation
Jump to search
scientific article published on 01 April 2004
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer |
scientific article published on 01 April 2004 |
Statements
Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer (English)
P Schöffski
B Thate
G Beutel
O Bolte
D Otto
M Hofmann
A Ganser
A Jenner
P Cheverton
J Wanders
T Oguma
R Atsumi